Zeria Pharmaceutical Co Ltd

Zeria Pharmaceutical Co Ltd maintains a conservative capital structure with a debt-to-equity ratio of 0.47, indicating a balanced approach to financing. The company's liquidity position is characterized as medium, with a current ratio of 1.28, suggesting it can meet short-term obligations but with limited excess cash. Free cash flow of ¥12.81 billion supports operational flexibility and potential reinvestment. Profitability metrics show a return on equity (ROE) of 11.1% and a return on assets (ROA) of 6.24%, both above the typical thresholds for pharmaceutical firms, indicating strong asset utilization and profitability. The company's operating margin of 13.7% (calculated from operating income of ¥11.97 billion on revenue of ¥87.31 billion) is robust, reflecting efficient cost management. Zeria's revenue is concentrated in Japan, with no disclosed international segments, making it highly sensitive to domestic market conditions and regulatory changes. The company does not report revenue by product segment, but its focus on both innovative and generic drugs suggests a diversified product portfolio within the domestic market. The company's revenue growth is expected to remain stable, with no significant changes in the near term. Analysts have set a mean price target of ¥2,500, which is 5.9% above the current market price of ¥2,380, suggesting a modest upside. Historical revenue trends show a consistent but moderate growth trajectory, with no signs of rapid expansion or contraction. Zeria faces medium liquidity risk due to its current ratio of 1.28, which is just above the threshold for concern. The company's dilution risk is low, with no significant dilution sources identified in recent filings. However, the company's net cash position is negative after subtracting total debt, which could limit its ability to pursue aggressive growth strategies without additional financing. Recent events include the publication of its latest financial results, which showed a net income of ¥9.94 billion and a gross profit of ¥63.96 billion. The company has not disclosed any major new product launches or regulatory approvals in the most recent quarter, but its ongoing R&D efforts are expected to support future growth.